Results 71 to 80 of about 23,148 (170)

Metabolic Dysfunction‐Associated Fatty Liver Disease: From Pathogenesis to Treatment

MedComm, Volume 7, Issue 7, July 2026.
Extracellular vesicles play a crucial role in interorgan crosstalk of adipose–liver and gut–liver axes and hold potential as therapeutic targets and drug delivery systems for metabolic dysfunction‐associated fatty liver disease (MAFLD). Abbreviations: AT: adipose tissue; EVs: extracellular vesicles; HL: healthy liver; NAFL: nonalcoholic fatty liver ...
Zhifu Cui, Xiaxia Du, Felix Kwame Amevor, Yaoyao Xia, You Yang, Lingbin Liu   +5 more
wiley   +1 more source

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

Cost Effectiveness and Resource Allocation, 2009
Background The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk ...
Massi-Benedetti Massimo, Erny-Albrecht Katrina M, Goodall Gordon, Scherbaum Werner A, Erdmann Erland, Valentine William J   +5 more
doaj   +1 more source

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5704-5714, July 2026.
ABSTRACT Background Metabolic dysfunction–associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve metabolic control while preventing advanced liver outcomes are limited.
Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel   +4 more
wiley   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5834-5847, July 2026.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6405-6412, July 2026.
ABSTRACT Aims Oral semaglutide absorption is subject to inter‐individual variability. We investigated whether estimated individual exposure (eC avg ) provides predictive information beyond the prescribed dose in a real‐world cohort of patients with type 2 diabetes (T2D).
Gian Paolo Fadini, Mario Luca Morieri, Carlotta Boscaro, Benedetta Maria Bonora, Andrea Cignarella   +4 more
wiley   +1 more source

Effects of Resveratrol on pharmacokinetics and pharmacodynamics of Pioglitazone in Diabetic rats [PDF]

Perspectives In Medical Research, 2017
Introduction: Diabetes is a group of metabolic disorders characterized by a chronic hyperglycaemic condition resulting from insufficient action of insulin.
Raju Devde1 , Narasimha Reddy Y2 , Sravanthi K3 , Abid Ali4 , Imran Khan5
doaj  

Efficacy of pioglitazone in treatment of metabolic dysfunction-associated fatty liver disease

Al-Azhar Assiut Medical Journal
Background and aim Nonalcoholic fatty liver disease has emerged as a major public health challenge, with limited approved pharmacological therapies.
Mahmoud M. Khafagi, Hamdy M. Moustafa, Ahmed A. Ahmed, Mohamed A. Bashir, Abdelghany Aish, Amro M. Hassan   +5 more
doaj   +1 more source

Identification of Potential Therapeutic Targets in the Liver of Pioglitazone-Treated Type 2 Diabetes Sprague-Dawley Rats via Expression Profile Chip and iTRAQ Assay

Journal of Diabetes Research, 2018
The aim of the present study was to identify key antidiabetic nodes in the livers of pioglitazone-treated type 2 diabetes mellitus Sprague-Dawley rats by transcriptomic and proteomic analysis.
Zhong-Xia Lu, Wen-Jun Xu, Yang-Sheng Wu, Chang-Yu Li, Yi-Tao Chen   +4 more
doaj   +1 more source

Pioglitazone

Journal of Postgraduate Medicine, 2014
S S, Jadhav, V K, Shivane, A R, Lila, T R, Bandgar, N S, Shah   +4 more
openaire   +3 more sources

Pioglitazone: Indian perspective

Indian Journal of Endocrinology and Metabolism, 2011
Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance.
Rishi Shukla, Sanjay Kalra
doaj